Abbott Laboratories has won US antitrust approval to buy Alere on condition that it sell two point-of-care medical testing businesses, the Federal Trade Commission said on Thursday, September 28.
Canada also announced on Thursday that it had approved the proposed transaction on similar terms.
Abbott first offered to buy Alere in February 2016, but the deal ran into trouble because of issues related to the diagnostic maker’s accounting and sales practices. The company finally agreed to buy Alere in April for about US$5.3 billion, down from an initial US$5.8 billion offer.
Alere also agreed Thursday to pay more than US$13 million to resolve Securities and Exchange Commission charges that it committed accounting fraud and made improper payments to foreign officials.
To win the US antitrust approval, the FTC required Abbott to sell two types of point-of-care medical testing device businesses, which can be used in doctors’ offices, hospitals and homes.
The companies agreed to divest a blood gas testing system that measures the oxygen and carbon dioxide in the blood and a cardiac marker system used to determine quickly if a patient is having a heart attack or congestive heart failure.
Full Content: Seeking Alpha
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Health Care Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
NY AG Joins Suit Challenging NCAA’s Restrictions on Student Athlete NIL Rights
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI